Compare MFIC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | XERS |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | MFIC | XERS |
|---|---|---|
| Price | $11.02 | $6.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $11.25 | $10.83 |
| AVG Volume (30 Days) | 616.8K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | ★ $10.50 | $636.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $9.48 | $4.30 |
| 52 Week High | $13.51 | $10.08 |
| Indicator | MFIC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 51.90 |
| Support Level | $10.92 | $6.26 |
| Resistance Level | $11.81 | $6.41 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 8.82 | 28.50 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.